tirzepatide approval Day 4: Zepbound (Tirzepatide – weight loss indication) FDA Approved: November 2023 for weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management Tirzepatide for Weight Loss Receives

10.1161/CIR.0000000000001063 36 HouseA

The JAK1/STAT3 pathway was implicated in this mechanism, and the beneficial effects of melatonin were partially diminished when a JAK1 inhibitor was administered, indicating the importance of this pathway in mediating the effects of melatonin (Shukla et al., 2017)

These results established tirzepatides superiority over the then-dominant GLP-1 standard of care and drove rapid uptake following the May 2022 Mounjaro approval

Ads for Mounjaro and Ozempic emphasizes protection against heart disease and diabetes, with weight loss an extra benefit

We queried the TCGA database of human PTC tumor specimens (N = 501) using TIMER 2.0 computational platform